Yttrium-ibritumomab (Zevalin) + Rituximab
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell
Trial Timeline
Apr 1, 2002 → Feb 1, 2010
NCT ID
NCT00038623About Yttrium-ibritumomab (Zevalin) + Rituximab
Yttrium-ibritumomab (Zevalin) + Rituximab is a phase 2 stage product being developed by Biogen for Lymphoma, Mantle-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT00038623. Target conditions include Lymphoma, Mantle-Cell.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00038623 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma, Mantle-Cell